

DYLAN KELLACHAN
Vice President

Direct: 617 422 2525
Fax: 617 425 8001
dylan.kellachan@analysisgroup.com

111 Huntington Avenue
14th Floor
Boston, MA 02199

Mr. Kellachan applies his experience in quantitative and qualitative analysis to litigation and non-litigation business matters related to antitrust and competition, health care, finance, and commercial disputes. His antitrust and competition experience includes evaluating allegations of reverse-payment settlements between pharmaceutical companies and potential abuse of US Food and Drug Administration (FDA) regulatory frameworks, and assessing damages claims in a variety of industry contexts. His securities and finance work has involved analyzing the merits of clawing back compensation from executives at a national bank following a high-profile scandal and assessing whether executives failed to enable a strong safety culture or disclose risks following adverse events. Mr. Kellachan also has experience with commercial disputes regarding the national distribution and dispensation of controlled substances and the application of organizational theory to matters involving product liability, safety, and risk management. He has supported academic and industry experts through all phases of litigation, including expert search, fact discovery, expert testimony, trial preparation, and settlement negotiations.

EDUCATION

2018 M.B.A., business analytics, quantitative finance, and strategy (*with distinction*), NYU Stern School of Business
2012 B.A., philosophy and English (*magna cum laude*), Boston College

PROFESSIONAL EXPERIENCE

2018–Present, Analysis Group, Inc.
2012–2016 *Vice President (2025–Present)*
Manager (2022–2024)
Associate (2018–2021)
Senior Analyst (2014–2016)
Analyst (2012–2014)
2017 National Hockey League
Student Mentor, Club Business & Analytics

SELECTED CONSULTING EXPERIENCE

Antitrust and Competition

- **Claims of anticompetitive patent listing behavior**
Supported an expert engaged by the defendant to address FDA regulatory issues. Evaluated the opposing experts' opinions that the defendant allegedly listed a patent improperly in FDA's Orange Book to delay competitive entry.
- **Pharmaceutical class action**
Supported an expert engaged by defendants to evaluate the opposing expert's analysis of damages to direct purchasers of a drug product following alleged "bribes" paid by the drug manufacturer in the form of rebates, fees, and other payments.
- ***In re: Lipitor Antitrust Litigation***
US District Court, District of New Jersey
Supported an expert engaged by the defendants to address FDA regulatory issues. Evaluated the opposing expert's opinion that generic entry would have occurred sooner but for an allegedly unlawful reverse-payment settlement agreement between the defendants.
- ***Federal Trade Commission, et al. v. Vyera Pharmaceuticals, LLC, et al.***
US District Court, Southern District of New York
Assisted an expert engaged by the defendants to address competitive effects issues. Evaluated the opposing experts' analysis of practices related to drug distribution and active pharmaceutical ingredient supply.
- **Pharmaceutical class action**
Supported an expert in reverse-payment settlement class action lawsuits. Evaluated the terms and structure of an at-issue pharmaceutical alliance agreement by overseeing an analysis of hundreds of similar agreements.
- ***In re: Loestrin 24 FE Antitrust Litigation***
US District Court, District of Rhode Island
Supported an expert in an alleged reverse-payment settlement and an alleged anticompetitive product-switching strategy involving oral contraceptives.
- ***In re: TFT-LCD (Flat Panel) Antitrust Litigation***
US District Court, Western District of Washington; US District Court, Northern District of California, San Francisco Division
Supported experts in the analysis of liability issues and damages related to price-fixing allegations.

Commercial Disputes

- **Product liability matter in the consumer health products industry**
Supported a management and organizational behavior expert in assessing how a major life sciences organization responded to allegations of adverse outcomes resulting from the use of a widely used consumer health care product. Evaluated whether and to what extent the organization prioritized consumer safety in the investigation of the allegations.

- ***In re: National Prescription Opiate Litigation***

US District Court, Northern District of Ohio, Eastern Division

On behalf of a national chain pharmacy, supported an expert in the evaluation of issues related to the identification of suspicious orders of opiates, and harm resulting from alleged suspicious orders.

Securities and Finance

- **Government investigation into clawback of executive compensation**

Assessed the impact of a high-profile banking scandal on the financial performance of a bank. Supported expert testimony regarding the impact on company financials, stock price, and executive compensation. Addressed qualitative arguments regarding whether the scandal could have been anticipated or prevented by the bank.

- **Claims of material misrepresentation and failure of executives to disclose risks**

Supported a management and organizational behavior expert in assessing the impact of a high-profile adverse outcome for a global mining company. Evaluated whether and to what extent executives and senior officers of the company focused on safety and risk management.

- **Executive breach of fiduciary duty**

Supported a management and organizational behavior expert in assessing the impact of high-profile adverse outcomes for an investor-owned utility. Evaluated whether and to what extent board members and senior officers of the utility enabled a strong safety culture and prioritized safety.

Intellectual Property

- **Patent infringement of vaccine technology**

Supported a defense expert in an assessment of vaccine development. Evaluated the factors, apart from the accused vaccine technology, that contributed to the success of a vaccine product and identified risks defendants took in developing and launching the vaccine.

SELECTED HONORS AND AWARDS

2018 Glucksman Fellowship, Glucksman Institute for Research in Securities Markets, NYU Stern School of Business

2017 Zelin Family Scholarship, NYU Stern School of Business

PROFESSIONAL ASSOCIATIONS AND MEMBERSHIPS

2018–Present Beta Gamma Sigma

LANGUAGES

Spanish (basic)